WeVote
Log In

Bill

Bill

HD 2752

An Act relative to copay assistance for medications

194th Legislature (2025-2026) Introduced by Manny Cruz

Massachusetts bill regulating copay assistance programs to reduce high-cost medication promotion while balancing patient affordability against system-wide insurance cost growth.

0
WeVote Research Nonpartisan
Bill Summary · HD 2752

Legislative bill overview

HD 2752 would regulate copay assistance programs that help patients afford high-cost medications by limiting how these programs operate and what they can cover. The bill aims to address concerns about pharmaceutical manufacturers using copay assistance to circumvent insurance cost-sharing and promote expensive brand-name drugs over generics or biosimilars.

Why is this important

Copay assistance programs affect medication affordability for patients with chronic conditions, but they can inflate overall healthcare costs by reducing price transparency and encouraging use of higher-cost alternatives. This creates tension between individual patient affordability and systemic cost control—assistance that helps one patient may drive up premiums and costs for the broader insurance pool.

Potential points of contention

  • Restrictions on copay assistance eligibility: Limiting which patients can receive assistance or which medications qualify could leave vulnerable patients unable to afford necessary treatments
  • Generic and biosimilar incentives: Requirements to prioritize generics may reduce assistance for brand-name drugs, helping costs but potentially limiting patient choice and clinical flexibility
  • Manufacturer incentives: Regulations could reduce pharmaceutical companies' motivation to offer copay programs, potentially leaving uninsured and underinsured patients with fewer affordability options

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.